Publication: Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand
Issued Date
1999-12-01
Resource Type
ISSN
00221899
DOI
Other identifier(s)
2-s2.0-0033383602
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infectious Diseases. Vol.180, No.4 (1999), 1282-1287
Suggested Citation
Douglas S. Walsh, Sornchai Looareesuwan, Polrat Wilairatana, D. Gray Heppner, Douglas B. Tang, Thomas G. Brewer, Watcharee Chokejindachai, Parnpen Viriyavejakul, Dennis E. Kyle, Wilbur K. Milhous, Brian G. Schuster, John Horton, David J. Braitman, Ralf P. Brueckner Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. Journal of Infectious Diseases. Vol.180, No.4 (1999), 1282-1287. doi:10.1086/315034 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25422
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand
Abstract
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.